Skip to Content
Exit Menu
Dr Luigi Margiotta-Casaluci

Dr Luigi Margiotta-Casaluci
Visiting Senior Lecturer - Life Sciences

Membership and affiliation

Member of :

  • Society of Safety Pharmacology (SPS)
  • Society of Environmental Toxicology and Chemistry (SETAC)
  • Steering Committee of the SETAC Interest Group “Artificial Intelligence and Toxicology”

Media interests


The research carried out by the Margiotta-Casaluci Lab continues to have a significant impact on the pharmaceutical indutry sector. His recent article " Pharmacology beyond the patient – The environmental risks of human drugs " has been featured on the website of the pharmaceutical company AstraZeneca. The hotspot article is available here.  


In 2018/2019, Dr Margiotta-Casaluci has secured funding from the NC3Rs to develop a model that portrays the relationship between the blockade of the L-type calcium channels and heart failure. This type of model, known as Adverse Outcome Pathways (AOP), has the potential to support drug safety assessment by providing a mechanistic framework to guide hypothesis generation, data interpretation, and effects prediction. The output of this project has been used as one of 12 case studies in the NC3Rs Research Review 2019, showcasing key NC3Rs-funded research carried out in the last 5 years. Being selected as one of the 12 case study has been a great honour and achievement, as it highlights both the impact and the high quaility of his research.    

The description of the project is available here; whereas the NC3Rs Research Review 2019 can be downloaded from this link


In 2018, Dr Margiotta-Casaluci was thrilled to receive the Junior Investigator Award of Society of Safety Pharmacology (SPS). Thanks to the Award, he was able to present his work on cardiotoxicity at the annual meeting in Washinghton DC, where he received a great welcome from the SPS community. 


In 2016, Dr Margiotta-Casaluci led the development of a quantitative Adverse Outcome Pathway (qAOP) network that links the in vitro poly-pharmacology profile of beclomethasone dipropionate (BDP) – a drug used to treat asthma - to multiple cascades of effects characterized experimentally. This qAOP network was the first to explicitly consider the critical role of internal exposure dynamics, chemical-specific properties, and study design in AOP development, and represented a significant step forward in the field.

The work, described in an article published in Nature Scientific Reports, has been highlighted by several non-specialsit media - including Medical News Today and La Razon - and in the NC3Rs AOP Newsletter of July 2016.